Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) CFO Alan A. Musso sold 6,206 shares of Bellicum Pharmaceuticals stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $9.89, for a total transaction of $61,377.34. The sale was disclosed in a filing with the SEC, which is available through this link.

Shares of Bellicum Pharmaceuticals, Inc. (BLCM) traded up $0.02 during mid-day trading on Wednesday, reaching $9.75. 214,000 shares of the company traded hands, compared to its average volume of 600,214. Bellicum Pharmaceuticals, Inc. has a 12-month low of $7.41 and a 12-month high of $20.19. The company has a quick ratio of 6.08, a current ratio of 6.08 and a debt-to-equity ratio of 0.23.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.03. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 77.16%. The firm had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.03 million. During the same period last year, the firm posted ($0.66) EPS. The firm’s quarterly revenue was up 18.2% on a year-over-year basis. equities research analysts expect that Bellicum Pharmaceuticals, Inc. will post -2.94 EPS for the current fiscal year.

Several equities analysts recently issued reports on the stock. ValuEngine raised shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, September 18th. Raymond James Financial set a $18.00 price target on shares of Bellicum Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Jefferies Group reissued a “buy” rating and set a $16.00 price target on shares of Bellicum Pharmaceuticals in a report on Thursday, September 14th. BidaskClub downgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Finally, Zacks Investment Research raised shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 24th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $26.20.

Institutional investors and hedge funds have recently bought and sold shares of the business. Voya Investment Management LLC acquired a new stake in Bellicum Pharmaceuticals in the 2nd quarter valued at about $132,000. Commonwealth Equity Services Inc acquired a new stake in Bellicum Pharmaceuticals in the 3rd quarter valued at about $142,000. American International Group Inc. increased its position in Bellicum Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 852 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Bellicum Pharmaceuticals in the 3rd quarter valued at about $164,000. Finally, Nationwide Fund Advisors increased its position in Bellicum Pharmaceuticals by 30.4% in the 2nd quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 3,620 shares in the last quarter. Hedge funds and other institutional investors own 54.38% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/11/29/bellicum-pharmaceuticals-inc-blcm-cfo-sells-61377-34-in-stock.html.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Insider Buying and Selling by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Stock Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.